RxDoctor Payments Data

Jan Fujita, MD

Obstetrics & Gynecology · Aiea, HINPI 1316055726

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 62 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by Amgen at 35.7% of the total. Reporting peaked in 2019 at $352 and has fallen 52.1% since, to $169 in 2025.

$1,349in general payments, 2019–2025

Across 62 payments — averaging $21.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$482
  • Astellas Pharma US Inc$225
  • Bayer$191
  • AbbVie$159
  • KARL Storz Endoscopy-america$63
  • Exeltis, USA Inc.$49
  • plus $180 from 6 others

What the payments were for

  • Food & beverage$1,349100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,349 in reported general payments places this provider in the 75th percentile of 225 obstetrics & gynecology providers in Hawaii.

See all obstetrics & gynecology providers in Hawaii

Medicare billing

Part B allowed, 2024
$19,832
Medicare patients
112
Services billed
248

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ProliaDenosumab104$181,143
Raloxifene Hcl14$2,635
Alendronate Sodium74$2,184
Risedronate Sodium45$1,669
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip27$567
Losartan Potassium13$292

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenProlia$482$181,143104 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 225 obstetrics & gynecology providers in Hawaii.

Other obstetrics & gynecology in Aiea

See the full list for Hawaii

Where these figures come from

Is this you, or does something look wrong? →